Eosinophilic Esophagitis

SAN DIEGO — Treatment for eosinophilic esophagitis often involves collaboration between specialists, but patients face challenges in adherence, according to a pair of posters presented here.

SAN DIEGO — Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food elimination diets during treatment, according to a poster presented here.

Considering “paradigm-shifting changes” in the diagnosis and management of eosinophilic esophagitis, the ACG released an updated guideline on treatment, monitoring and maintenance as well as pediatric-specific recommendations.

Although this year brought many advances in the treatment of food allergy, the FDA’s approval of omalizumab dominated our most popular coverage.

A retrospective chart review revealed a 50% increase in outpatient pediatric psychology referrals from the Food Allergy Treatment Center between 2013 and 2023.

PHILADELPHIA — A once-weekly 360 mg dose of cendakimab sustained improvements in symptoms and endoscopic/histologic features of eosinophilic esophagitis at 48 weeks, according to data presented at the ACG Annual Scientific Meeting.

BOSTON — Children with atopic disease had increased risks for developing eosinophilic esophagitis, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Native American youth have increased odds for feeding tube placement, not receiving eosinophilic esophagitis treatment upon diagnosis and barriers to health care access, according to a study in Annals of Allergy, Asthma and Immunology.

The FDA approved ARS Pharmaceuticals’ neffy epinephrine nasal spray for emergency allergic reactions in children and adults weighing at least 66 pounds.

A novel peptide that uniquely affects the effector and regulatory arms of immune responses has potential for treating eosinophilic esophagitis and other allergic diseases, according to a press release from Revolo Biotherapeutics.